Liver Fat, Hepatic Enzymes, Alkaline Phosphatase and the Risk of Incident Type 2 Diabetes: A Prospective Study of 132,377 Adults

Scientific Reports

Volumn 7, Issue 1, 2017, Pages

  Chen, Sean Chun Chang ^a   Tsai, Shan Pou ^b   Jhao, Jing Yun ^b,c   Jiang, Wun Kai ^b,c   Tsao, Chwen Keng ^b   Chang, Ly Yun ^b,c,d  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b MJ Health Management Institution   (Taiwan)

^c MJ Group   (Taiwan)

^d INSTITUTE OF SOCIOLOGY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE;

ADULT; AGED; COMPLICATION; ENZYMOLOGY; FEMALE; HUMAN; LIVER; MALE; METABOLISM; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; PROSPECTIVE STUDY; REGRESSION ANALYSIS; RISK FACTOR;

ADULT; AGED; ALANINE TRANSAMINASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASES; DIABETES MELLITUS, TYPE 2; FEMALE; GAMMA-GLUTAMYLTRANSFERASE; HUMANS; LIVER; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PROSPECTIVE STUDIES; REGRESSION ANALYSIS; RISK FACTORS;

EID: 85021992177     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/s41598-017-04631-7     Document Type: Article

References (44)

1. Chan, J. C. et al. Diabetes in Asia: epidemiology, risk factors, and pathophysiology. JAMA 301, 2129-2140, doi:10.1001/jama.2009.726(2009).
2. Emerging Risk Factors, C. et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 364, 829-841, doi:10.1056/NEJMoa1008862 (2011).
3. Knowler, W. C. et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New Engl J Med 346, 393-403 (2002).
4. Fraser, A. et al. Alanine aminotransferase, gamma-glutamyltransferase, and incident diabetes: the British Women's Heart and Health Study and meta-analysis. Diabetes Care 32, 741-750, doi:10.2337/dc08-1870 (2009).
5. Hanley, A. J. et al. Elevations in markers of liver injury and risk of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes 53, 2623-2632 (2004).
6. Ohlson, L. O. et al. Risk factors for type 2 (non-insulin-dependent) diabetes mellitus. Thirteen and one-half years of follow-up of the participants in a study of Swedish men born in 1913. Diabetologia 31, 798-805 (1988).
7. Sattar, N. et al. Elevated alanine aminotransferase predicts new-onset type 2 diabetes independently of classical risk factors, metabolic syndrome, and C-reactive protein in the west of Scotland coronary prevention study. Diabetes 53, 2855-2860 (2004).
8. Vozarova, B. et al. High alanine aminotransferase is associated with decreased hepatic insulin sensitivity and predicts the development of type 2 diabetes. Diabetes 51, 1889-1895 (2002).
9. Wannamethee, S. G., Shaper, A. G., Lennon, L. & Whincup, P. H. Hepatic enzymes, the metabolic syndrome, and the risk of type 2 diabetes in older men. Diabetes Care 28, 2913-2918, doi:10.2337/diacare.28.12.2913 (2005).
10. Andre, P. et al. Hepatic markers and development of type 2 diabetes in middle aged men and women: a three-year follow-up study - The DESIR study (Data from an Epidemiological Study on the Insulin Resistance syndrome). Diabetes & Metabolism 31, 542-550, doi:10.1016/S1262-3636(07)70229-X (2005).
11. Schneider, A. L. C. et al. Liver enzymes, race, gender and diabetes risk: the Atherosclerosis Risk in Communities (ARIC) Study. Diabetic Med 30, 926-933, doi:10.1111/dme.12187 (2013).
12. Kunutsor, S. K., Abbasi, A. & Apekey, T. A. Aspartate aminotransferase - risk marker for type-2 diabetes mellitus or red herring? Front Endocrinol (Lausanne) 5, 189, doi:10.3389/fendo.2014.00189 (2014).
13. Liu, J., Au Yeung, S. L., Lin, S. L., Leung, G. M. & Schooling, C. M. Liver Enzymes and Risk of Ischemic Heart Disease and Type 2 Diabetes Mellitus: A Mendelian Randomization Study. Sci Rep 6, 38813, doi:10.1038/srep38813 (2016).
14. Noordam, R., Smit, R. A., Postmus, I., Trompet, S. & van Heemst, D. Assessment of causality between serum gammaglutamyltransferase and type 2 diabetes mellitus using publicly available data: a Mendelian randomization study. Int J Epidemiol. doi:10.1093/ije/dyw306 (2016).
15. Lee, Y. S. et al. Serum gamma-glutamyl transferase and risk of type 2 diabetes in the general Korean population: a Mendelian randomization study. Hum Mol Genet 25, 3877-3886, doi:10.1093/hmg/ddw226 (2016).
16. Seppala-Lindroos, A. et al. Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. J Clin Endocr Metab 87, 3023-3028, doi:10.1210/jc.87.7.3023 (2002).
17. Bhatt, H. B. & Smith, R. J. Fatty liver disease in diabetes mellitus. Hepatobiliary Surg Nutr 4, 101-108, doi:10.3978/j.issn.2304- 3881.2015.01.03 (2015).
18. Kasturiratne, A. et al. Influence of non-alcoholic fatty liver disease on the development of diabetes mellitus. J Gastroen Hepatol 28, 142-147, doi:10.1111/j.1440-1746.2012.07264.x (2013).
19. Kim, C. H., Park, J. Y., Lee, K. U., Kim, J. H. & Kim, H. K. Fatty liver is an independent risk factor for the development of Type 2 diabetes in Korean adults. Diabet Med 25, 476-481, doi:10.1111/j.1464-5491.2008.02410.x (2008).
20. Li, W. D. et al. Comparison of effects of obesity and non-alcoholic fatty liver disease on incidence of type 2 diabetes mellitus. World J Gastroenterol 21, 9607-9613, doi:10.3748/wjg.v21.i32.9607 (2015).
21. Shibata, M., Kihara, Y., Taguchi, M., Tashiro, M. & Otsuki, M. Nonalcoholic fatty liver disease is a risk factor for type 2 diabetes in middle-aged Japanese men. Diabetes Care 30, 2940-2944, doi:10.2337/dc07-0792 (2007).
22. Sung, K. C., Jeong, W. S., Wild, S. H. & Byrne, C. D. Combined Influence of Insulin Resistance, Overweight/Obesity, and Fatty Liver as Risk Factors for Type 2 Diabetes. Diabetes Care 35, 717-722, doi:10.2337/dc11-1853 (2012).
23. Sung, K. C., Wild, S. H. & Byrne, C. D. Resolution of Fatty Liver and Risk of Incident Diabetes. J Clin Endocr Metab 98, 3637-3643, doi:10.1210/jc.2013-1519 (2013).
24. Yamazaki, H., Tsuboya, T., Tsuji, K., Dohke, M. & Maguchi, H. Independent Association Between Improvement of Nonalcoholic Fatty Liver Disease and Reduced Incidence of Type 2 Diabetes. Diabetes Care 38, 1673-1679, doi:10.2337/dc15-0140 (2015).
25. Westerbacka, J. et al. Women and men have similar amounts of liver and intra-abdominal fat, despite more subcutaneous fat in women: implications for sex differences in markers of cardiovascular risk. Diabetologia 47, 1360-1369, doi:10.1007/s00125-004- 1460-1 (2004).
26. Tibi, L., Collier, A., Patrick, A. W., Clarke, B. F. & Smith, A. F. Plasma alkaline phosphatase isoenzymes in diabetes mellitus. Clin Chim Acta 177, 147-155 (1988).
27. Perry, I. J., Wannamethee, S. G. & Shaper, A. G. Prospective study of serum gamma-glutamyltransferase and risk of NIDDM. Diabetes Care 21, 732-737, doi:10.2337/diacare.21.5.732 (1998).
28. Nannipieri, M. et al. Liver enzymes, the metabolic syndrome, and incident diabetes: The Mexico City Diabetes Study. Diabetes Care 28, 1757-1762, doi:10.2337/diacare.28.7.1757 (2005).
29. Jiang, Y. D., Chang, C. H., Tai, T. Y., Chen, J. F. & Chuang, L. M. Incidence and prevalence rates of diabetes mellitus in Taiwan: analysis of the 2000-2009 Nationwide Health Insurance database. J Formos Med Assoc 111, 599-604, doi:10.1016/j.jfma.2012.09.014 (2012).
30. Lin, C. C. et al. Time trend analysis of the prevalence and incidence of diagnosed type 2 diabetes among adults in Taiwan from 2000 to 2007: a population-based study. Bmc Public Health 13, doi:10.1186/1471-2458-13-318 (2013).
31. Chitturi, S. et al. Non-alcoholic fatty liver disease in the Asia-Pacific region: Definitions and overview of proposed guidelines. J Gastroen Hepatol 22, 778-787, doi:10.1111/j.1440-1746.2007.05001.x (2007).
32. Lazo, M. et al. Prevalence of Nonalcoholic Fatty Liver Disease in the United States: The Third National Health and Nutrition Examination Survey, 1988-1994. Am J Epidemiol 178, 38-45, doi:10.1093/aje/kws448 (2013).
33. Riley, T. R. & Kahn, A. Risk factors and ultrasound can predict chronic hepatitis caused by nonalcoholic fatty liver disease. Digest Dis Sci 51, 41-44, doi:10.1007/s10620-006-3082-6 (2006).
34. Mulhall, B. P., Ong, J. P. & Younossi, Z. M. Non-alcoholic fatty liver disease: An overview. J Gastroen Hepatol 17, 1136-1143, doi:10.1046/j.1440-1746.2002.02881.x (2002).
35. Ryan, C. K., Johnson, L. A., Germin, B. I. & Marcos, A. One hundred consecutive hepatic biopsies in the workup of living donors for right lobe liver transplantation. Liver Transplant 8, 1114-1122, doi:10.1053/jlts.2002.36740 (2002).
36. Perez, N. E. et al. Ultrasound diagnosis of fatty liver in patients with chronic liver disease - A retrospective observational study. J Clin Gastroenterol 41, 624-629, doi:10.1097/01.mcg.0000225680.45088.01 (2007).
37. Tolman, K. G., Fonseca, V., Dalpiaz, A. & Tan, M. H. Spectrum of liver disease in type 2 diabetes and management of patients with diabetes and liver disease. Diabetes Care 30, 734-743, doi:10.2337/dc06-1539 (2007).
38. Ozyilkan, E. & Arslan, M. Increased prevalence of diabetes mellitus in patients with chronic hepatitis C virus infection. Am J Gastroenterol 91, 1480-1481 (1996).
39. Oh, S. W., Han, K. H. & Han, S. Y. Associations between Renal Hyperfiltration and Serum Alkaline Phosphatase. Plos One 10, doi:10.1371/journal.pone.0122921 (2015).
40. Vora, J. P. et al. Renal hemodynamics in newly presenting non-insulin dependent diabetes mellitus. Kidney Int 41, 829-835 (1992).
41. Nakanishi, N. et al. Serum gamma-glutamyltransferase and development of impaired fasting glucose or type 2 diabetes in middleaged Japanese men. J Intern Med 254, 287-295, doi:10.1046/j.1365-2796.2003.01198.x (2003).
42. Lazo, M., Selvin, E. & Clark, J. M. Brief communication: Clinical implications of short-term variability in liver function test results. Ann Intern Med 148, 348-W376 (2008).
43. Wang, M. L. MJ Health Screening Equipment Use and Replacement Records. MJ Health Research Foundation Technical Report MJHRF-TR-06 (2016).
44. Wen, C. P. et al. Minimum amount of physical activity for reduced mortality and extended life expectancy: a prospective cohort study. Lancet 378, 1244-1253, doi:10.1016/S0140-6736(11)60749-6 (2011).